Characteristics and influencing factors of immune-related adverse events in patients with extensive-stage small cell lung cancer treated with immune checkpoint inhibitors

WU Qiong; HUANG Qichun; QIN Zhongyu; LIAO Liufeng

doi:10.6039/j.issn.1001-0408.2024.22.14

您当前的位置：

首页 >

文章列表页 >

Characteristics and influencing factors of immune-related adverse events in patients with extensive-stage small cell lung cancer treated with immune checkpoint inhibitors

更新时间：2025-09-24

- Characteristics and influencing factors of immune-related adverse events in patients with extensive-stage small cell lung cancer treated with immune checkpoint inhibitors
- ZHONGGUO YAOFANG Vol. 35, Issue 22, Pages: 2784-2788(2024)
- 作者机构：
  
  1.广西医科大学附属肿瘤医院药学部，南宁　530021
  2.广西壮族自治区药品不良反应监测中心，南宁　530021
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.22.14
  CLC： R979.1
- Received：19 June 2024，
  
  Revised：2024-10-29，
  
  Accepted：04 November 2024，
  
  Published：30 November 2024
- 稿件说明：
移动端阅览
吴琼,黄其春,覃忠于,等.广泛期小细胞肺癌患者使用免疫检查点抑制剂发生免疫相关不良事件的特征及影响因素[J].中国药房,2024,35(22):2784-2788.

WU Qiong,HUANG Qichun,QIN Zhongyu,et al.Characteristics and influencing factors of immune-related adverse events in patients with extensive-stage small cell lung cancer treated with immune checkpoint inhibitors[J].ZHONGGUO YAOFANG,2024,35(22):2784-2788.
吴琼,黄其春,覃忠于,等.广泛期小细胞肺癌患者使用免疫检查点抑制剂发生免疫相关不良事件的特征及影响因素[J].中国药房,2024,35(22):2784-2788. DOI： 10.6039/j.issn.1001-0408.2024.22.14.

WU Qiong,HUANG Qichun,QIN Zhongyu,et al.Characteristics and influencing factors of immune-related adverse events in patients with extensive-stage small cell lung cancer treated with immune checkpoint inhibitors[J].ZHONGGUO YAOFANG,2024,35(22):2784-2788. DOI： 10.6039/j.issn.1001-0408.2024.22.14.

摘要

目的

探讨广泛期小细胞肺癌患者使用免疫检查点抑制剂（ICIs）发生免疫相关不良事件（irAEs）的临床特征及影响因素。

方法

利用中国医院药物警戒系统回顾性收集我院2023年1月1日至5月31日使用ICIs的130例广泛期小细胞肺癌患者的资料，记录所有患者治疗期间irAEs的发生情况及激素使用情况。采用多因素Logistic回归模型分析影响irAEs发生的因素。

结果

纳入的130例患者中，有32例患者发生了38例次irAEs，发生率为24.6%，严重程度为1～3级；以皮肤症状（8.4%）最为常见，且集中发生在治疗的第1个周期；5例患者发生多器官系统irAEs。发生irAEs患者的激素使用不合理率为23.1%（甲状腺功能异常患者除外）。神经元特异性烯醇化酶（NSE）为影响irAEs发生的独立因素（

＜0.05）。

结论

ICIs 所致的irAEs发生率较高，可累及全身各个器官系统，以皮肤症状发生最早；NSE是影响irAEs发生的独立因素，可一定程度预测irAEs的发生风险。

Abstract

OBJECTIVE

To explore the clinical characteristics and influencing factors of immune-related adverse events （irAEs） in patients with extensive-stage small cell lung cancer （SCLC） treated with immune checkpoint inhibitors （ICIs）.

METHODS

The data from 130 patients with extensive-stage SCLC treated with ICIs at our hospital from January 1， 2023， to May 31， 2023 was collected retrospectively using the Chinese Hospital Pharmacovigilance System. The occurrence of irAEs and the use of corticosteroids during treatment for all patients were recorded. A multifactorial Logistic regression model was used to analyze the influencing factors for the occurrence of irAEs.

RESULTS

Among the 130 patients included， 32 patients experienced 38 episodes of irAEs， with an incidence rate of 24.6% and severity of degree 1-3. Skin symptoms were the most common （8.4%） and predominantly occurred in the first cycle of treatment. Five patients developed irAEs involving multiple organ systems. The irrational use rate of corticosteroids in patients with irAEs was 23.1% （excluding patients with thyroid dysfunction）. Neuron specific enolase （NSE） was a independent factor influencing the occurrence of irAEs （

＜0.05）.

CONCLUSIONS

The incidence of irAEs caused by ICIs remains relatively high and can involve various organ systems throughout the body， with skin symptoms occurring earliest. NSE is an independent influencing factor for the occurrence of irAEs， and could predict the risk of irAEs to a certain extent.

关键词

Keywords

references

BYUN D J ， WOLCHOK J D ， ROSENBERG L M ， et al . Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies [J ] . Nat Rev Endocrinol ， 2017 ， 13 （ 4 ）： 195 - 207 .

赵喆，唐彦，朱惠娟，等 . 免疫检查点抑制剂引发的免疫相关不良反应研究进展 [J ] . 临床药物治疗杂志， 2022 ， 20 （ 6 ）： 1 - 6 .

ZHAO Z ， TANG Y ， ZHU H J ， et al . Progress in immune-related adverse events induced by immune checkpoint inhibitors [J ] . Clin Med J ， 2022 ， 20 （ 6 ）： 1 - 6 .

LI D J ， XU X L ， LIU J H ， et al . Small cell lung cancer（SCLC） incidence and trends vary by gender，geography，age，and subcategory based on population and hospital cancer registries in Hebei，China：2008-2017 [J ] . Thorac Cancer ， 2020 ， 11 （ 8 ）： 2087 - 2093 .

SINGH H ， BEAVER J A ， PAZDUR R . Immunotherapy for patients with small-cell lung cancer-2 gains，2 losses [J ] . JAMA Oncol ， 2022 ， 8 （ 1 ）： 37 - 38 .

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会（CSCO）免疫检查点抑制剂相关的毒性管理指南：2023 [M ] . 北京：人民卫生出版社， 2023 ： 13 .

Guidelines Working Committee of the Chinese Society of Clinical Oncology . Guidelines of Chinese Society of Clinical Oncology（CSCO）management of immune checkpoint inhibitor-related toxicity：2023 [M ] . Beijing ： People’s Health Publishing House ， 2023 ： 13 .

JING Y ， YANG J W ， JOHNSON D B ， et al . Harnessing big data to characterize immune-related adverse events [J ] . Nat Rev Clin Oncol ， 2022 ， 19 （ 4 ）： 269 - 280 .

Institute NC . Common terminology criteria for adverse events（CTCAE） [EB/OL ] .（ 2020-03-25 ）[ 2022-01-28 ] . https：//ctep.cancer.gov/protocolDevelopment/electronic_ applications/ctc.htm https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm .

HAVEL J J ， CHOWELL D ， CHAN T A . The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy [J ] . Nat Rev Cancer ， 2019 ， 19 （ 3 ）： 133 - 150 .

ZHENG F ， MENG Q J ， ZHANG L ， et al . Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors：a retrospective cohort study [J ] . World J Surg Oncol ， 2023 ， 21 （ 1 ）： 198 .

COSTANTINI A ， TAKAM K P ， JULIE C ， et al . Plasma biomarkers screening by multiplex ELISA assay in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors [J/OL ] . Cancers（Basel）， 2020 ， 13 （ 1 ）： 97 [ 2022-02-10 ] . https：//www.mdpi.com/2072-6694/13/1/97 https://www.mdpi.com/2072-6694/13/1/97 . DOI： 10.3390/cancers13010097 http://dx.doi.org/10.3390/cancers13010097 .

PHILLIPS G S ， WU J ， HELLMANN M D ， et al . Treatment outcomes of immune-related cutaneous adverse events [J ] . J Clin Oncol ， 2019 ， 37 （ 30 ）： 2746 - 2758 .

WANG Y H ， ZONG B G ， YU Y ， et al . Ki67 index changes and tumor-infiltrating lymphocyte levels impact the prognosis of triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy [J ] . Front Oncol ， 2021 ， 11 ： 668610 .

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会（CSCO）小细胞肺癌诊疗指南：2024 [M ] . 北京：人民卫生出版社， 2024 ： 50 .

Guidelines Working Committee of the Chinese Society of Clinical Oncology . Guidelines of Chinese Society of Clinical Oncology（CSCO）small-cell lung cancer：2024 [M ] . Beijing ： People’s Health Publishing House ， 2024 ： 50 .

吴建辉，储香玲，王李强，等 . 中国肺癌患者真实世界免疫检查点抑制剂相关性肺炎的流行病学分析 [J ] . 中国癌症杂志， 2022 ， 32 （ 6 ）： 469 - 477 .

WU J H ， CHU X L ， WANG L Q ， et al . Epidemiological analysis of real-world immune checkpoint inhibitor-related pneumonitis in Chinese patients with lung cancer [J ] . China Oncol ， 2022 ， 32 （ 6 ）： 469 - 477 .

TANG S Q ， TANG L L ， MAO Y P ， et al . The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer：a pooled analysis of 23 clinical trials and 8 436 patients [J ] . Cancer Res Treat ， 2021 ， 53 （ 2 ）： 339 - 354 .

WANG Y C ， ZHOU S H ， YANG F ， et al . Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials：a systematic review and meta-analysis [J ] . JAMA Oncol ， 2019 ， 5 （ 7 ）： 1008 - 1019 .

牛志成，王雷，汪治宇 . 免疫检查点抑制剂相关不良反应的管理专家共识 [J ] . 河北医科大学学报， 2021 ， 42 （ 3 ）： 249 - 255 .

NIU Z C ， WANG L ， WANG Z Y . Expert consensus on management of adverse reactions related to inhibitors at immune checkpoints [J ] . J Hebei Med Univ ， 2021 ， 42 （ 3 ）： 249 - 255 .

吕明闯，王红岩 . 血清神经元特异性烯醇化酶、胃泌素释放肽前体在小细胞肺癌中的表达意义 [J ] . 河南医学研究， 2022 ， 31 （ 7 ）： 1219 - 1222 .

LYU M C ， WANG H Y . Significance of expression of serum neuron specific enolase and progastrin-releasing peptide in small cell lung carcinoma [J ] . Henan Med Res ， 2022 ， 31 （ 7 ）： 1219 - 1222 .

Views

149

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical efficacy and influencing factors of ceftazidime and avibactam monotherapy versus combination therapy in the treatment of CRGNB infection

Study on the influential factors for clinical efficacy of polymyxin B combined with other antibiotics in the treatment of carbapenem-resistant Acinetobacter baumannii pulmonary infection

Investigation on the current status of pharmaceutical care in medical institutions in China

Analysis of the standardization and influential factors in the prevention and treatment of glucocorticoid-induced osteoporosis with drugs

Analysis of factors influencing immune checkpoint inhibitor-related thyroid adverse reactions

Related Author

LIU Changwei

WANG Xiaohua

ZHANG Hui

WANG Ranran

XIAO Rongcheng

FANG Ling

DU Mei

TAN Ruijuan

Related Institution

Dept. of Infectious Diseases， the First Affiliated Hospital of Anhui Medical University

Grade Ⅲ Pharmaceutical Chemistry Laboratory of TCM， National Administration of Traditional Chinese Medicine

Dept. of Pharmacy， the First Affiliated Hospital of Anhui Medical University

Dept. of Rehabilitation Medicine， Hengshui Municipal People’s Hospital

Dept. of Pharmacy， Hengshui Municipal People’s Hospital

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰